O Albania Department of NeuroIntegrin beta 2/CD18 Proteins Recombinant Proteins Sciences, Mario Negri Institute for Pharmacological Investigation IRCCS, Milan, Italy; bMolecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; c Department of Clinical Neurosciences, Faculty of Brain Sciences, University College London Institute of Neurology, London, UKacPOSTECH, Pohang, Republic of Korea; Department of Urology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea; Division of Laboratory Medicine, Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea, Seoul; dDepartment of Mechanical Engineering, POSTECH, Pohang, Republic of KoreabIntroduction: Analysing extracellular B7-H6 Proteins web vesicles (EVs) is definitely an eye-catching implies in prostate cancer diagnosis. Even so, existing procedures of EVs isolation have low efficiency, purity and extended approach time, which induce low diagnostic ability. To approach the troubles, we adapt a two-phase technique to diagnose prostate cancer by isolating EVs from patients’ urine. Making use of the twophase system, prostate hyperplasia (BPH) patients and prostate cancer (PCA) individuals have been diagnosed, and theIntroduction: Extracellular vesicles (EVs) represent an ideal source of biomarkers because of their function in cellular communication and their capability to carry protein aggregates. One of the most investigated EVs are exosomes, active entities secreted from cells and able to cross the blood brain barrier. A number of neurodegeneration-involved molecules may perhaps undergo intercellular spreading via exosome release. In Alzheimer’s disease (AD), just before clinical signs seem, a number of proteins implicated in exo- and endocytic pathways are altered. In thisJOURNAL OF EXTRACELLULAR VESICLESscenario, the identification of a correlation between variations in proteins carried by EVs and the progression of AD will be the key aim of our project. Procedures: We performed exosome isolation and characterization from H4-SW glioma cells (a cell model featuring mutated -amyloid overexpression), at the same time as in mouse(triple-transgenic mouse model for familial AD) and human-plasma samples (Mild Cognitive Impairment (MCI) and AD subjects). In each and every case, a differential centrifugation protocol was applied and exosomes have been then characterized working with Nanoparticle Tracking Analysis with the NanoSight. We then explored exosome content, specifically Amyloid Precursor Protein (APP) and its proteolytic fragments, Microtubule Connected Protein Tau (tau), Progranulin (PGRN protein), Soluble Triggering Receptor Expressed on Myeloid Cells two (sTREM2) and synuclein (-syn), working with Western blot and ELISA. L1CAM and CD63 had been evaluated to define the neural-derived exosomes amount in human samples. All the samples had been collected after ethical committee approval respecting Helsinki’s declaration. Informed consents were supplied by all the subjects. Benefits: Our preliminary results show that APP, PGRN and sTREM2 are carried by H4- and human plasmaderived EVs. H4-SW cell-culture medium and 3Tg mouse plasma had a lower inside the EVs number release (110e8 EVs/mL) in comparison to manage (710e8 EVs/mL). This reduce was not found in human plasma samples. Summary/Conclusion: EVs purified from H4-glioma cellular AD model, 3xTg mouse-, MCI- and ADplasma samples carry proteins relevant for neurodegenerative illnesses (NDs). EVs release is reduced in cellular and animal AD-models. Funding: Horizon 2020 Marie Sklodowska-Curie Revolutionary Education Networks Blood Biomarker-ba.